image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Essentra - £5m reduction in costs

October 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • ESNT
  • Price:
  • 145.5p
I caught up with CEO Scott Fawcett again on the day of Essentra’s interims. The highlight was a £5m reduction in central costs (£2m more than previously planned) which meant it met expectations for EBIT profit of £23m, up 52% year-on-year (eps: 5.9p). The double-digit volume decreases, offset by 7-8% price rises, leave sales down 5.5% overall. Those savings powered a 5.2% increase in EBIT margin to 13.8%. Fawcett’s plan is to hit 18% medium-term. Macro factors led to tough conditions. EMEA was broadly flat, but the outlook has downside risk due to weakness in Germany. The Americas fell 12.6% and even though de-stocking continues, it could recover quicker than expected with US inflation coming under control. Asia fell 18.3% but wit ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author